Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 11/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309649 | 1.00 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL13309648 | 1.00 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3421997 | 0.92 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3264612 | 0.92 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3230127 | 0.87 | IRAK4 (0.39) | SYKVCPTACR3 | |
| SCHEMBL3228769 | 0.87 | IRAK4 (0.39) | SYKVCPTACR3 | |
| SCHEMBL3264514 | 0.86 | CAMK2D (0.43) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3420476 | 0.86 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3234459 | 0.86 | CAMK2D (0.45) | CAMK2DPLK1LDHALDHBSYK | |
| SCHEMBL3263499 | 0.86 | CAMK2D (0.43) | CAMK2DPLK1LDHALDHBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | CAMK2D 1584/4885PLK1 3165/4885LDHA 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.